Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Discovery World

NOVEMBER 17, 2022

It is believed that the term synthetic biology was created in 1970 by geneticist, Waclaw Szybalski 1 as work was being carried out on the development of DNA sequencing and synthesis techniques. These factors can significantly contribute to the growth of the synthetic biology market, it adds. . Brady and colleagues turned to algorithms.

Engineering 130

Engineering Molecular Biology Synthetic Chemistry DNA 130

Drug Discovery World

APRIL 30, 2024

“This recognition has led to the development of programs encompassing vaccines, RNAi, and small molecules that span diverse therapeutic areas. It’s worth noting that the approach of small molecules interacting with mRNA biology represents a relatively new and potentially broader and more effective strategy.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. .

Drugs 246

Drugs Disease Drug Development Therapies 246

Codon

MARCH 20, 2023

Point-of-care peptide hormone production enabled by cell-free protein synthesis. Marine biofilm engineered to produce current in response to small molecules. Digital nanoreactors to control absolute stoichiometry and spatiotemporal behavior of DNA receptors within lipid bilayers. DeWinter MA. ACS Synthetic Biology.

Virus 52

Virus Engineering RNA Small Molecule 52

Drug Discovery World

NOVEMBER 13, 2023

Michael Traxlmayr, PhD, Group leader, CD Laboratory for Next-Generation CAR T Cells, University of Natural Resources & Life Sciences, on: ‘Novel concepts to regulate CAR T cell activity with small molecule drugs in vivo’. These topics include: High-throughput (HTP) protein production and AI and automation in bioprocess development.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

Codon

MAY 30, 2023

This week: A way to measure a transgene’s expression in the brain using ultrasound, a DNA sequencing method that uses 1000x less reagents, and base editors get even smaller. An engineered version of this protein can convert DNA bases with efficiencies up to 92%. so this Digest will be published more irregularly.

DNA 52

DNA RNA Engineering Vaccine 52